Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 7;384(1):80-82.
doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Alicia T Widge  1 , Nadine G Rouphael  2 , Lisa A Jackson  3 , Evan J Anderson  2 , Paul C Roberts  4 , Mamodikoe Makhene  4 , James D Chappell  5 , Mark R Denison  5 , Laura J Stevens  5 , Andrea J Pruijssers  5 , Adrian B McDermott  4 , Britta Flach  4 , Bob C Lin  4 , Nicole A Doria-Rose  4 , Sijy O'Dell  4 , Stephen D Schmidt  4 , Kathleen M Neuzil  6 , Hamilton Bennett  7 , Brett Leav  7 , Mat Makowski  8 , Jim Albert  8 , Kaitlyn Cross  8 , Venkata-Viswanadh Edara  2 , Katharine Floyd  2 , Mehul S Suthar  2 , Wendy Buchanan  4 , Catherine J Luke  4 , Julie E Ledgerwood  4 , John R Mascola  4 , Barney S Graham  4 , John H Beigel  4 ; mRNA-1273 Study Group
Collaborators, Affiliations

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Alicia T Widge et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Time Course of SARS-CoV-2 Antibody Binding and Neutralization Responses after mRNA-1273 Vaccination.
Shown are data from 34 participants who were stratified according to age: 18 to 55 years of age (15 participants), 56 to 70 years of age (9 participants), and 71 years of age or older (10 participants). All the participants received 100 μg of mRNA-1273 on days 1 and 29, indicated by arrows. The titers shown are the binding to spike receptor–binding domain (RBD) protein (the end-point dilution titer) assessed on enzyme-linked immunosorbent assay (ELISA) on days 1, 15, 29, 36, 43, 57, and 119 (Panel A); the 50% inhibitory dilution (ID50) titer on pseudovirus neutralization assay on days 1, 15, 29, 36, 43, 57, and 119 (Panel B); the ID50 titer on focus reduction neutralization test mNeonGreen (FRNT-mNG) assay on days 1, 29, 43, and 119 (Panel C); and the 80% inhibitory dilution (ID80) titer on plaque-reduction neutralization testing (PRNT) assay on days 1, 43, and 119 (Panel D). Data for days 43 and 57 are missing for 1 participant in the 18-to-55-year stratum for whom samples were not obtained at those time points. Each line represents a single participant over time.
See this image and copyright information in PMC

References

    1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med 2020;383:1920-1931. - PMC - PubMed
    1. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 10.1056/NEJMoa2028436. - DOI - PMC - PubMed
    1. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 2020;383:1724-1734. - PMC - PubMed
    1. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. November 16, 2020. (https://www.biorxiv.org/content/10.1101/2020.11.15.383323v1). preprint.
    1. Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020;584:437-442. - PMC - PubMed

Publication types